Axial
@axial.bsky.social
Agency for great inventors https://linktr.ee/axialxyz
Expanding RNA's purview to more diseases. With the key caveat of excluding siRNA.
October 31, 2023 at 3:04 PM
Expanding RNA's purview to more diseases. With the key caveat of excluding siRNA.
And offer almost a one-stop shop
From a technical perspective, Orbital is bringing technologies together to improve the durability of therapeutic RNA candidates and apply them to a broader range of cell types and tissues
From a technical perspective, Orbital is bringing technologies together to improve the durability of therapeutic RNA candidates and apply them to a broader range of cell types and tissues
October 31, 2023 at 3:04 PM
And offer almost a one-stop shop
From a technical perspective, Orbital is bringing technologies together to improve the durability of therapeutic RNA candidates and apply them to a broader range of cell types and tissues
From a technical perspective, Orbital is bringing technologies together to improve the durability of therapeutic RNA candidates and apply them to a broader range of cell types and tissues
The long-term idea is to use patient data generated to support discovery and development of new therapies. Bring various parts together where Scipher partners with payers, providers, and pharma companies to bring precision medicine products to patients.
October 30, 2023 at 2:25 PM
The long-term idea is to use patient data generated to support discovery and development of new therapies. Bring various parts together where Scipher partners with payers, providers, and pharma companies to bring precision medicine products to patients.
They received Medicare coverage in 2023 for their PrismRA test which guides treatment selection for rheumatoid arthritis patients.
Studies show when PrismRA guides therapy, patients are 3 times more likely to reach remission
Studies show when PrismRA guides therapy, patients are 3 times more likely to reach remission
October 30, 2023 at 2:25 PM
They received Medicare coverage in 2023 for their PrismRA test which guides treatment selection for rheumatoid arthritis patients.
Studies show when PrismRA guides therapy, patients are 3 times more likely to reach remission
Studies show when PrismRA guides therapy, patients are 3 times more likely to reach remission
To solve treatment resistance in cell-cycle driven cancers and expand the therapeutic window for patients
October 29, 2023 at 4:16 PM
To solve treatment resistance in cell-cycle driven cancers and expand the therapeutic window for patients
Focusing on two candidates to bring into the clinic: IAM-H1, a highly selective and brain-penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1, a potential first-in-class selective dual CDK2/4 inhibitor
October 29, 2023 at 4:16 PM
Focusing on two candidates to bring into the clinic: IAM-H1, a highly selective and brain-penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1, a potential first-in-class selective dual CDK2/4 inhibitor
Founded in 2019, the company is now building a pipeline of first-in-class and best-in-class programs. Key programs include HER2, CDK2/4 inhibitors along with newer targets.
October 29, 2023 at 4:16 PM
Founded in 2019, the company is now building a pipeline of first-in-class and best-in-class programs. Key programs include HER2, CDK2/4 inhibitors along with newer targets.
Using its platform, built on 4 technologies, to explore chemical space to hone in on mechanisms of action and generate diverse, high-quality leads.
October 29, 2023 at 4:16 PM
Using its platform, built on 4 technologies, to explore chemical space to hone in on mechanisms of action and generate diverse, high-quality leads.
Pfizer made an upfront cash payment of $25M to Dren Bio, with the company eligible to potentially receive more than $1B. To advance select oncology programs
October 27, 2023 at 12:07 AM
Pfizer made an upfront cash payment of $25M to Dren Bio, with the company eligible to potentially receive more than $1B. To advance select oncology programs
The second program uses a proprietary bispecific antibody platform to engage myeloid and cancer cells, reprogram the tumor environment, stimulate phagocytosis, and activate T cells for sustained anti-tumor immunity. Partnering with Pfizer in 2022 using technology behind Dren's second drug candidate
October 27, 2023 at 12:07 AM
The second program uses a proprietary bispecific antibody platform to engage myeloid and cancer cells, reprogram the tumor environment, stimulate phagocytosis, and activate T cells for sustained anti-tumor immunity. Partnering with Pfizer in 2022 using technology behind Dren's second drug candidate
The MoA is done through depletion of target cells via ADCC by means of fratricide, a method in which the same cell type induces ADCC on each other. A phase I/II trial has been initiated to assess the safety and efficacy of DR-01 in previously treated LGLL patients
October 27, 2023 at 12:06 AM
The MoA is done through depletion of target cells via ADCC by means of fratricide, a method in which the same cell type induces ADCC on each other. A phase I/II trial has been initiated to assess the safety and efficacy of DR-01 in previously treated LGLL patients
DR-01, the lead candidate, which induces antibody-mediated killing of cytotoxic immune cells involved in blood cancers. With potential use in autoimmune diseases too. The lead targets CD94 which is known to be up-regulated on large granular lymphocytic leukemia (LGLL) cells
October 27, 2023 at 12:06 AM
DR-01, the lead candidate, which induces antibody-mediated killing of cytotoxic immune cells involved in blood cancers. With potential use in autoimmune diseases too. The lead targets CD94 which is known to be up-regulated on large granular lymphocytic leukemia (LGLL) cells